Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects

NCT05077865 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Hashimoto Disease

Interventions

DRUG: MYMD-1
DRUG: Placebo

Sponsor

TNF Pharmaceuticals, Inc.